Giorgio Walter CanonicaLinda CoxRuby PawankarCarlos E. Baena-CagnaniMichael BlaissSergio BoniniJean BousquetMoises CalderónEnrico CompalatiStephen R. DurhamRoy Gerth Van WijkDésirée Larenas-LinnemannHarold NelsonGiovanni PassalacquaOliver PfaarNelson RosárioDermot RyanLanny RosenwasserPeter Schmid-GrendelmeierGianenrico SennaErkka ValovirtaHugo Van BeverPakit VichyanondUlrich WahnOsman YusufUniversita degli Studi di GenovaNova Southeastern UniversityNippon Medical SchoolCatholic UniversityUniversity of Tennessee Health Science CenterUniversita degli Studi di Napoli Federico IICHU MontpellierRoyal Brompton HospitalNational Heart and Lung InstituteErasmus University Medical CenterHospital Medica SurUniversity of Colorado School of MedicineOspedale Policlinico San MartinoUniversitatsklinikum MannheimUniversidade Federal do ParanaUniversity of AberdeenUniversity of Missouri-Kansas CityUniversity Hospital Zurich, Dermatologische KlinikVerona General HospitalNational University of SingaporeTurun yliopistoMahidol UniversityHumboldt-Universitat zu BerlinAllergy and Asthma Institute2018-11-092018-11-092014-03-28World Allergy Organization Journal. Vol.7, No.1 (2014)19394551193945512-s2.0-84902334391https://repository.li.mahidol.ac.th/handle/20.500.14594/33980© 2014 Canonica et al.; licensee BioMed Central Ltd. We have prepared this document, "Sublingual Immunotherapy: World Allergy Organization Position Paper 2013 Update", according to the evidence-based criteria, revising and updating chapters of the originally published paper, "Sublingual Immunotherapy: World Allergy Organization Position Paper 2009", available at. Namely, these comprise: "Mechanisms of sublingual immunotherapy;" "Clinical efficacy of sublingual immunotherapy" - reporting all the data of all controlled trials published after 2009; "Safety of sublingual immunotherapy" - with the recently published Grading System for adverse reactions; "Impact of sublingual immunotherapy on the natural history of respiratory allergy" - with the relevant evidences published since 2009; "Efficacy of SLIT in children" - with detailed analysis of all the studies; "Definition of SLIT patient selection" - reporting the criteria for eligibility to sublingual immunotherapy; "The future of immunotherapy in the community care setting"; "Methodology of clinical trials according to the current scientific and regulatory standards"; and "Guideline development: from evidence-based medicine to patients' views" - including the evolution of the methods to make clinical recommendations. Additionally, we have added new chapters to cover a few emerging crucial topics: "Practical aspects of schedules and dosages and counseling for adherence" - which is crucial in clinical practice for all treatments; "Perspectives and new approaches" - including recombinant allergens, adjuvants, modified allergens, and the concept of validity of the single products. Furthermore, "Raising public awareness about sublingual immunotherapy", as a need for our patients, and strategies to increase awareness of allergen immunotherapy (AIT) among patients, the medical community, all healthcare stakeholders, and public opinion, are also reported in detail.Mahidol UniversityImmunology and MicrobiologyMedicineReviewSCOPUS10.1186/1939-4551-7-6